- Home
- TBRG vs SKYE Comparison
TBRG vs SKYE Comparison
Compare TBRG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- SKYE
- Stock Information
- Founded
- TBRG 1979
- SKYE 2012
- Country
- TBRG United States
- SKYE United States
- Employees
- TBRG N/A
- SKYE N/A
- Industry
- TBRG
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- TBRG
- SKYE Health Care
- Exchange
- TBRG NYSE
- SKYE Nasdaq
- Market Cap
- TBRG 271.5M
- SKYE 94.0M
- IPO Year
- TBRG N/A
- SKYE N/A
- Fundamental
- Price
- TBRG $21.27
- SKYE $2.73
- Analyst Decision
- TBRG Buy
- SKYE Buy
- Analyst Count
- TBRG 3
- SKYE 6
- Target Price
- TBRG $14.67
- SKYE $18.67
- AVG Volume (30 Days)
- TBRG 78.7K
- SKYE 167.7K
- Earning Date
- TBRG 02-27-2025
- SKYE 02-09-2025
- Dividend Yield
- TBRG N/A
- SKYE N/A
- EPS Growth
- TBRG N/A
- SKYE N/A
- EPS
- TBRG N/A
- SKYE N/A
- Revenue
- TBRG $337,674,000.00
- SKYE N/A
- Revenue This Year
- TBRG $1.02
- SKYE N/A
- Revenue Next Year
- TBRG $6.06
- SKYE N/A
- P/E Ratio
- TBRG N/A
- SKYE N/A
- Revenue Growth
- TBRG 0.26
- SKYE N/A
- 52 Week Low
- TBRG $7.55
- SKYE $2.25
- 52 Week High
- TBRG $21.80
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- TBRG 74.93
- SKYE 37.40
- Support Level
- TBRG $20.62
- SKYE $2.31
- Resistance Level
- TBRG $21.80
- SKYE $3.04
- Average True Range (ATR)
- TBRG 0.72
- SKYE 0.30
- MACD
- TBRG 0.08
- SKYE 0.07
- Stochastic Oscillator
- TBRG 85.87
- SKYE 44.68
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.